Diagnostic and Therapeutic Dilemmas in Children and Adolescents with Bipolar Disorder

Bipolar Summit Web — Kiki D. Chang, MD — Nursing

Jointly provided by Postgraduate Institute for Medicine and Global Medical Education.

Supported by an independent educational grant from AstraZeneca Pharmaceuticals, Sunovion Pharmaceuticals, and Forest Pharmaceuticals.

Scroll to the Bottom of this Information to Begin This Course

Release date: October 10, 2014

Valid through: October 31, 2015

Specialty: Psychiatry

Topic: Bipolar Disorder

Estimated Time to Complete Activity: 1.25 hours

Target Audience:

This activity has been designed to meet the educational needs of physicians, nurse practitioners, physician assistants, registered nurses and other clinicians involved in the care of patients with bipolar disorder.

Learning Objectives:

Upon completion of this activity, participants should be better able to:

  • Recognize the clinical consequences for patients, as well as the impact on the larger healthcare system, of missed and incorrect diagnosis in bipolar patients.
  • Implement evidence-based recommendations to improve both symptomatic and functional outcomes in all phases of bipolar disorder.
  • Apply findings from research studies and expert recommendations that make patients active collaborators in their care to improve outcomes in special populations.
  • Design individualized medication and psychotherapy treatment strategies to improve outcomes based on the efficacy, safety, long-term data, and route of administration of the available therapies.
  • Provide appropriate care and counsel for patients and their families.

Credit Available

  • Nurses — 1.2 Nursing Contact Hours
    Designated for 0.5 contact hours of pharmacotherapy credit for APRNs.

Physicians and other health care professionals should take Understanding Bipolar and Related Disorders in the 21st Century: From Kraepelin to DSM-5 - Module 3 - Physician to recieve a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

All other health care professionals completing this course will be issued a statement of participation.


Kiki D. Chang, MD
Professor of Psychiatry and Behavioral Sciences
Division of Child Psychiatry
Stanford University School of Medicine Director,
Pediatric Bipolar Disorders Clinic
Stanford University School of Medicine

Nursing Continuing Education

Credit Designation

This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine.

Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Kiki D. Chang, MD
  • Consulting Fees: XXX

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Prakash Masand, MD: Consultant: Forest, Lundbeck, Merck, Pamlabs, Pfizer, Sunovion, Takeda; Research Support: Forest, Takeda; Speaker's Bureau: Forest, GlaxoSmithKline, Lundbeck, Merck, Pamlabs, Pfizer, Sunovion, Takeda

Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period October 10, 2014 through October 31, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.



Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.